Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Screening surgeons for HIV infection. A cost-effectiveness analysis.

Owens DK, Harris RA, Scott PM, Nease RF Jr.

Ann Intern Med. 1995 May 1;122(9):641-52.

PMID:
7702225
2.
3.

Cost-effectiveness of HIV screening in acute care settings.

Owens DK, Nease RF Jr, Harris RA.

Arch Intern Med. 1996 Feb 26;156(4):394-404.

PMID:
8607724
4.

Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.

Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, Douglass LR, Lazzeroni LC, Holodniy M, Owens DK.

N Engl J Med. 2005 Feb 10;352(6):570-85.

5.

The cost effectiveness of universal antenatal screening for HIV in New Zealand.

Bramley D, Graves N, Walker D.

AIDS. 2003 Mar 28;17(5):741-8.

PMID:
12646798
6.

Who should be screened for HIV infection? A cost-effectiveness analysis.

McCarthy BD, Wong JB, Muñoz A, Sonnenberg FA.

Arch Intern Med. 1993 May 10;153(9):1107-16.

PMID:
8481077
7.

The cost effectiveness of voluntary prenatal and routine newborn HIV screening in the United States.

Zaric GS, Bayoumi AM, Brandeau ML, Owens DK.

J Acquir Immune Defic Syndr. 2000 Dec 15;25(5):403-16.

PMID:
11141240
8.

Cost-effectiveness of targeted human immunodeficiency virus screening in an urban emergency department.

Dowdy DW, Rodriguez RM, Hare CB, Kaplan B.

Acad Emerg Med. 2011 Jul;18(7):745-53. doi: 10.1111/j.1553-2712.2011.01110.x.

10.

Cost-effectiveness analysis of screening health care workers for HIV.

Chavey WE, Cantor SB, Clover RD, Reinarz JA, Spann SJ.

J Fam Pract. 1994 Mar;38(3):249-57.

PMID:
8126405
11.

The costs, clinical benefits, and cost-effectiveness of screening for cervical cancer in HIV-infected women.

Goldie SJ, Weinstein MC, Kuntz KM, Freedberg KA.

Ann Intern Med. 1999 Jan 19;130(2):97-107.

PMID:
10068381
12.

Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.

Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.

Lung Cancer. 2005 May;48(2):171-85. Epub 2005 Jan 4.

PMID:
15829317
13.

A prospective study on the risk of exposure to HIV during surgery in Zambia.

Consten EC, van Lanschot JJ, Henny PC, Tinnemans JG, van der Meer JT.

AIDS. 1995 Jun;9(6):585-8.

PMID:
7662197
14.
15.

Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood.

AuBuchon JP, Birkmeyer JD, Busch MP.

Transfusion. 1997 Jan;37(1):45-51.

PMID:
9024489
16.

Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.

Pinkerton SD, Holtgrave DR, Pinkerton HJ.

Arch Intern Med. 1997 Sep 22;157(17):1972-80.

PMID:
9308509
17.

How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings.

Farnham PG, Sansom SL, Hutchinson AB.

Med Decis Making. 2012 May-Jun;32(3):459-69. doi: 10.1177/0272989X11431609. Epub 2012 Jan 12.

PMID:
22247422
18.

Screening and surveillance for Barrett esophagus in high-risk groups: a cost-utility analysis.

Inadomi JM, Sampliner R, Lagergren J, Lieberman D, Fendrick AM, Vakil N.

Ann Intern Med. 2003 Feb 4;138(3):176-86.

PMID:
12558356
19.

Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis.

Hu D, Hook EW 3rd, Goldie SJ.

Ann Intern Med. 2004 Oct 5;141(7):501-13. Erratum in: Ann Intern Med. 2004 Nov 2;141(9):744.

PMID:
15466767
20.

Human immunodeficiency virus retesting during pregnancy: costs and effectiveness in preventing perinatal transmission.

Sansom SL, Jamieson DJ, Farnham PG, Bulterys M, Fowler MG.

Obstet Gynecol. 2003 Oct;102(4):782-90.

PMID:
14551009

Supplemental Content

Support Center